Chemoinformaics analysis of 2-[5-(2-Hydroxy-propyl)-tetrahydrofuran-2-yl]-propionic acid, t-butyl ester
| Molecular Weight | 258.358 | nRot | 4 |
| Heavy Atom Molecular Weight | 232.15 | nRig | 6 |
| Exact Molecular Weight | 258.183 | nRing | 1 |
| Solubility: LogS | -2.207 | nHRing | 1 |
| Solubility: LogP | 2.068 | No. of Aliphatic Rings | 1 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 44 | No. of Aliphatic Hetero Cycles | 1 |
| No. of Heavy Atom | 18 | No. of Aromatic Carbocycles | 0 |
| nHetero | 4 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 26 | No. of Saturated Hetero Cycles | 1 |
| No. of Carbon atom | 14 | No. of Saturated Rings | 1 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 4 | No. of Arom Bond | 0 |
| nHA | 4 | APOL | 43.9246 |
| nHD | 1 | BPOL | 30.4234 |
| QED | 0.786 |
| Synth | 3.814 |
| Natural Product Likeliness | 1.58 |
| NR-PPAR-gamma | 0.283 |
| Lipinski | Accepted |
| Pfizer | Accepted |
| GSK | Accepted |
| Golden Triangle | Accepted |
| Pgp-inh | 0.017 |
| Pgp-sub | 0.006 |
| HIA | 0.002 |
| CACO-2 | -4.513 |
| MDCK | 0.000085 |
| BBB | 0.679 |
| PPB | 0.630198 |
| VDSS | 1.529 |
| FU | 0.460252 |
| CYP1A2-inh | 0.028 |
| CYP1A2-sub | 0.29 |
| CYP2c19-inh | 0.035 |
| CYP2c19-sub | 0.906 |
| CYP2c9-inh | 0.012 |
| CYP2c9-sub | 0.15 |
| CYP2d6-inh | 0.006 |
| CYP2d6-sub | 0.252 |
| CYP3a4-inh | 0.016 |
| CYP3a4-sub | 0.479 |
| CL | 12.401 |
| T12 | 0.483 |
| hERG | 0.008 |
| Ames | 0.07 |
| ROA | 0.018 |
| SkinSen | 0.103 |
| Carcinogencity | 0.891 |
| EI | 0.862 |
| Respiratory | 0.029 |
| NR-Aromatase | 0.012 |
| Antiviral | Yes |
| Prediction | 0.753013 |